Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous lung condition characterised by chronic respiratory symptoms, fixed airway obstruction and persistent inflammation that leads to a progressive airflow limitation. Although COPD has traditionally been linked to neutrophilic inflammation, recent studies have identified a subset of patients – approximately 20%–40% – with elevated eosinophil levels in blood and sputum. Emerging evidence suggests that eosinophilic inflammation has a pivotal role in a subset of COPD patients and may influence disease progression, exacerbation frequency and therapeutic responses. This narrative review provides a comprehensive analysis of the role of eosinophils in COPD with particular attention to their role as biomarkers in blood and sputum. We evaluate the prevalence of eosinophilic inflammation in COPD exanimating different thresholds used in blood and in sputum to define it. In addition, we focus on eosinophilic COPD phenotype as a treatable trait, emphasising recent evidence that supports the effectiveness of biological target therapy.
Extract Asthma is a heterogeneous disease, generally characterised by chronic inflammation of the airways. Phenotyping has recently become a core tool to optimise its management and treatment [1] and biomarkers identification is now even more crucial. Blood eosinophils count is the most widely available inflammatory biomarker used for both therapeutic guidance and monitoring treatment response. Induced sputum (IS) is the gold-standard for a non-invasive assessment of airway inflammatory cell distribution. Four patterns have been identified based on the percentage of eosinophils and neutrophils in IS: eosinophilic, neutrophilic, mixed granulocytic and pauci-granulocytic [2].
(1) Background: “Brittle Asthma” was considered an asthma clinical phenotype and deemed to be life-threatening in the early 2000s; then, this definition disappeared. The purpose of this review is to examine what has historically been referred to as this term and see whether it may be applied to modern clinical practice, thus acquiring fresh relevance and meaning. (2) Methods: A non-systematic search of the literature was conducted using both MeSH and free-text phrases. No limitations on the research design or type of publication were applied. (3) Results: Reliable data regarding “Brittle Asthma” are lacking due to the paucity of current data and the few studies available. After a few years of reworking, it was divided into two sub-classes: one characterized by a wide PEF variability despite high-dose therapy and the other by sudden acute attacks in otherwise apparently normal airway functions or well-controlled asthma. Their characteristics were hardly defined because of their low prevalence. Data regarding risk factors, atopy, mechanisms, and treatments were analyzed. (4) Conclusions: Over time, different terminology has been introduced to define asthma severity and control. It would be worth investigating whether the term “Brittle Asthma” previously used may be helpful to find new hints to stratify patients and improve disease management.
Extract The management of severe asthma has been redefined by targeted biologic therapies [1], changing not only patient outcomes but also the way treatment success is conceptualized and measured [2]. Traditional frameworks categorized clinical benefit from non-response to response, mainly based on exacerbation reduction and oral corticosteroid (OCS) sparing [3, 4]. Recently, remission has emerged as a more ambitious treatment goal, integrating absence of exacerbations and OCS use with adequate symptom control and preserved or stable lung function [5, 6].
Background: Anti-IL5 receptor α is used to reduce the number of exacerbations and improve disease control in T2 severe asthma patients. Aims and Objectives: To evaluate the effects of anti-IL5 receptor α on systemic and airway inflammation, disease control, lung function in real life T2 severe asthmatic patients after 12-month treatment. Methods: A retrospective study has been conducted in our severe asthma centre. A comparison of clinical, functional, and inflammatory (induced sputum eosinophils-SE and blood eosinophils-BE) characteristics were assessed at baseline (T0) and after 12 months of treatment (T12). Results: 17 patients [median (IQR) age 56 (48.5-61.5) years; 6 (35.3%) males] with severe asthma were enrolled. At T12 after anti IL-5 receptor α treatment, a significant improvement in FEV1% [median (IQR) (79 (59-101.5) to 93 (79.8-104.0); p=0.006] and FEF 25-75% [median (IQR) 55.0 (32.5-85.5) to 88 (49-104); p=0.036] was observed, with a normalization of the Tiffenau index [median (IQR) 67.8 (57.0-76.7) to 77.1 (67.1-81.1); p=0.011)]. A significant reduction of exacerbations (p=0.001), OCS dose (p=0.005) and Asthma Control Test score was observed (p=0.001). The ability of sputum production was significantly reduced (p=0.031) as well as SE% [median (IQR) 57.1 (13.0-79.9) to 0 (0-0.3); (p=0.018)] and BE count [median (IQR) 620 (270.8-845.7) to 0 (0-0); (p<0.001)] and BE% (p<0.001). Conclusions: After 12 months of treatment with anti-IL-5 receptor α, improvement of FEV1% and FEF 25-75%, normalization of Tiffenau index and increase of disease control were accompanied by a significant decrease in the rate of expectoration ability and by a substantial reduction in both systemic and airway eosinophilic inflammation.